AcelRx initiated with a Buy at Alliance Global Partners

Alliance Global Partners initiated coverage of AcelRx Pharmaceuticals with a Buy rating and $4.25 price target. If approved, the analyst believes Niyad could take substantial share in the continuous renal replacement therapy market, where over 50% of patients can’t take standard Heparin and must rely on a “complicated” Citrate anti-coagulant or not use anything. The firm sees “multiple catalysts coming near term” for shares of AcelRx.